IOM: FDA Needs Post-Market Muscle To Follow Biomarker-Based Approvals
This article was originally published in The Gray Sheet
Executive Summary
Congress should give FDA more authority to require post-market surveillance of medical products approved primarily based on surrogate endpoints, the Institute of Medicine recommends